NTLA · Intellia Therapeutics Inc
United States · RS rating 52 · As of 2026-11-03
| Price | 11.86 USD |
|---|---|
| 1-day change | +1.7% |
| RS rating (overall / 1M / 3M / 12M) | 52 / 41 / 80 / 46 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 32 / 32 / 33 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | +9.8% |
| Sales growth Q/Q | +67.0% |
| Distance from 52-week high | +33.5% |
| Market cap (USD) | $1.9B |